المؤلفون: Mejía, Juan Armando, García Rairan, Luis, Figueredo, Luisa, Niño, Claudia

مصطلحات موضوعية: Hemorragia subaracnoidea aneurismática, Neuropéptido, Vasoespasmo, Biomarcador, Aneurysmal subarachnoid hemorrhage, Neuropeptide, Vasospasm, Biomarker

وصف الملف: application/pdf

Relation: World Neurosurgery: X, 2590-1397, 20, 2023, 1-2; https://www.sciencedirect.com/science/article/pii/S2590139723000728?via%3Dihub; http://hdl.handle.net/20.500.12495/11157; https://doi.org/10.1016/j.wnsx.2023.100223; instname:Universidad El Bosque; reponame:Repositorio Institucional Universidad El Bosque; repourl:https://repositorio.unbosque.edu.co

الاتاحة: https://hdl.handle.net/20.500.12495/11157
https://doi.org/10.1016/j.wnsx.2023.100223

المؤلفون: Cardona, Andrés F, Chamorro Ortiz, Diego Fernando, Ruíz-Patiño, Alejandro, Gomez, Diego, Muñoz, Álvaro, Ardila, Dora V, Garcia-Robledo, Juan Esteban, Ordóñez-Reyes, Camila, Sussmann, Liliana, Mosquera, Andrés, Forero, Yency, Rojas, Leonardo, Hakim, Fernando, Jimenez, Enrique, Ramón, Juan Fernando, Cifuentes, Hernando, Pineda, Diego, Mejía, Juan Armando, Rodríguez, July, Archila, Pilar, Sotelo, Carolina, Moreno-Pérez, Darwin A, Arrieta, Oscar

المساهمون: Applied Cancer Research, Foundation for Clinical

المصدر: Neuro-Oncology Practice ; volume 10, issue 4, page 381-390 ; ISSN 2054-2577 2054-2585

الاتاحة: https://doi.org/10.1093/nop/npad014
https://academic.oup.com/nop/advance-article-pdf/doi/10.1093/nop/npad014/50097383/npad014.pdf
https://academic.oup.com/nop/article-pdf/10/4/381/50876693/npad014.pdf

المؤلفون: Mejía, Juan Armando¹ (AUTHOR), Rairan, Luis Garcia² (AUTHOR) Lagarciar@unbosque.edu.co

المصدر: Egyptian Journal of Neurology, Psychiatry & Neurosurgery. 9/26/2024, Vol. 60 Issue 1, p1-6. 6p.

مصطلحات موضوعية: *CRANIAL nerves, *VAGUS nerve, *TRAPEZIUS muscle, *STERNOCLEIDOMASTOID muscle, *NEURALGIA

المؤلفون: Hakim, Fernando, Juan Fernando Ramón, Gómez, Diego F., Ghotme, Kemel A., Mejía, Juan Armando, Jimenez, Enrique, González, Martina, Jaramillo Velásquez, Daniel, Dominguez, Maria Teresa, Araque, Yesid, Cardenas, Maria Fernanda, Vallejo, Maria del Carmen, Soto, Hugo Alfredo, Espejo, Alfonso, Martinez, Carlos Fernando, Mayorga, Maria del Pilar, Hurtado, Cethinia, Cruz, Francy, Guacaneme, Francy, Ortega, Leidy Johana, Daza, Marcela

المصدر: Universidad de La Sabana ; Intellectum Repositorio Universidad de La Sabana

مصطلحات موضوعية: Normal pressure hydrocephalus, Syndrome, Ventriculoatrial shuntCenter of excellence

Relation: Interdisciplinary Neurosurgery Volume 28, June 2022, 101506; Hakim, F., Ramón, J. F., Gómez, D. F., Ghotme, K. A., Mejía, J. A., Jimenez, E., . & Daza, M. (2022). Proposal for a normal pressure hydrocephalus syndrome center of excellence. Interdisciplinary Neurosurgery, 28, 101506.; https://www.sciencedirect.com/science/article/pii/S2214751922000202; http://hdl.handle.net/10818/54092

الاتاحة: http://hdl.handle.net/10818/54092
https://www.sciencedirect.com/science/article/pii/S2214751922000202

المؤلفون: Cañas , Alejandro, Jiménez , Enrique, Hakim , Fernando, Mejía , Juan Armando, Ramón , Juan Fernando, Gómez , Diego, Jaramillo-Velásquez , Daniel, Bermúdez , Sonia, Useche , Nicolás, Pineda , Diego, Cifuentes , Hernando, Becerra, Antonio, Muñoz , Álvaro, Santoyo , Nicolás, Ruíz-Patiño , Alejandro, Sotelo , Carolina, Archila , Pilar, Rodríguez , July, Ávila , Jenny, Ordoñez-Reyes, Camila, García-Robledo , Juan Esteban, Ricaurte , Luisa, Rojas , Leonardo, Feo , Oscar, Burgos , Remberto, Ramírez , Carlos, Arrieta , Oscar, Zatarain-Barrón , Lucía, Vargas , Carlos, Carranza , Hernán, Otero , Jorge, Cardona , Andrés F.

المصدر: Biomedica; Vol. 42 No. 4 (2022); 574-590 ; Biomédica; Vol. 42 Núm. 4 (2022); 574-590 ; 2590-7379 ; 0120-4157

مصطلحات موضوعية: Meningioma, gain-of-function mutation, telomerase, meningoma, mutación con ganancia de función, telomerasa

وصف الملف: application/pdf; text/xml

Relation: https://revistabiomedica.org/index.php/biomedica/article/view/6100/5188; https://revistabiomedica.org/index.php/biomedica/article/view/6100/5101; https://revistabiomedica.org/index.php/biomedica/article/view/6100/5199; Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. “Malignancy” in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer. 1999;85:2046-56. https://doi.org/10.1002/(sici)1097-0142(19990501)85:93.0.co;2-m; Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. https://doi.org/10.1007/s00401-007-0243-4; Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19(Suppl.5):v1-88. https://doi.org/10.1093/neuonc/nox158; Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, et al. Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathol. 2015;25:266-75. https://doi.org/10.1111/bpa.12174; Wang YC, Chuang CC, Wei KC, Chang CN, Lee ST, Wu CT, et al. Long term surgical outcome and prognostic factors of atypical and malignant meningiomas. Sci Rep. 2016;6:35743. https://doi.org/10.1038/srep35743; Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, et al. WHO grade II and III meningiomas: A study of prognostic factors. J Neurooncol. 2009;95:367-75. https://doi.org/10.1007/s11060-009-9934-0; Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, et al. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun. 2017;8:186. https://doi.org/10.1038/s41467-017-00174-7; Christiaans I, Kenter SB, Brink HC, van Os TA, Baas F, van den Munckhof P, et al. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet. 2011;48:93-7. https://doi.org/10.1136/jmg.2010.082420; Bi WL, Abedalthagafi M, Horowitz P, Agarwalla PK, Mei Y, Aizer AA, et al. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016;125:525-35. https://doi.org/10.3171/2015.6.JNS15591; Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077-80. https://doi.org/10.1126/science.1233009; Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. Brain Tumor Pathol. 2016;33:237-47. https://doi.org 10.1007/s10014-016-0271-7; Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, et al. Erratum: Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017;2:26. https://doi.org/10.1038/s41525-017-0023-6; Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol. 2002;12:183-90. https://doi.org/10.1111/j.1750-3639.2002.tb00433.x; Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D, et al. Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol. 2021;23:783-94. https://doi.org/10.1093/neuonc/noaa226; Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017;19:535-45. https://doi.org/10.1093/neuonc/now235; Smith MJ, O’Sullivan J, Bhaskar SS, Hadfield KD, Poke G, Caird J, et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet. 2013;45:295-8. https://doi.org/10.1038/ng.2552; Tauziede-Espariat A, Parfait B, Besnard A, Lacombe J, Pallud J, Tazi S, et al. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: A comprehensive immunophenotypical and molecular analysis. Brain Pathol. 2018;28:466-74. https://doi.org/10.1111/bpa.12524; Vasudevan H, Braunstein S, Phillips JJ, Pekmezci M, Wu A, Reis G, et al. GENE-04. Comprehensive genomic characterization of aggressive meningiomas identifies molecular signatures that predict clinical outcomes. Neuro-Oncology. 2017;19(Suppl.6):vi92-3. https://doi.org/10.1093/neuonc/nox168.379; Barthel FP, Wei W, Tang M, Martínez-Ledesma E, Hu X, Amin SB, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017;49:349-57. https://doi.org/10.1038/ng.3781; Yuan P, Cao J lin, Abuduwufuer A, Wang LM, Yuan XS, Lv W, et al. Clinical characteristics and prognostic significance of TERT promoter mutations in cancer: A cohort study and a meta-analysis. PLoS ONE. 2016;11:e0146803. https://doi.org/10.1371/journal.pone.0146803; Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, et al. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017;8:109228-37. https://doi.org/10.18632/oncotarget.22650; Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T, et al. De novo and secondary anaplastic meningiomas: A study of clinical and histomolecular prognostic factors. Neuro Oncol. 2018;20:1113-21. https://doi.org/10.1093/neuonc/nox231; Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108:djv377. https://doi.org/10.1093/jnci/djv377; Spiegl-Kreinecker S, Lötsch D, Neumayer K, Kastler L, Gojo J, Pirker C, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 2018;20:1584-93. https://doi.org/10.1093/neuonc/noy104; Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016;131:803-20. https://doi.org/10.1007/s00401-016-1545-1; Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: Report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019;21:26-36. https://doi.org/10.1093/neuonc/noy137; Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110:6021-6. https://doi.org/10.1073/pnas.1303607110; Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018;18:241-9. https://doi.org/10.1080/14737175.2018.1429920; Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24:184-9. https://doi.org/10.1111/bpa.12110; Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: An individual patient data meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91:378-87. https://doi.org/10.1136/jnnp-2019-322257; Harmancı AS, Youngblood MW, Clark VE, Coşkun S, Henegariu O, Duran D, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2018;9:16215. https://doi.org/10.1038/ncomms14433; Maier A, Brøchner CB, Bartek J, Eriksson F, Ugleholdt H, Broholm H, et al. Mitotic and proliferative indices in WHO grade III meningioma. Cancers (Basel). 2020;12:E3351. https://doi.org/10.3390/cancers12113351; Maier AD, Stenman A, Svahn F, Mirian C, Bartek J, Juhler M, et al. TERT promoter mutations in primary and secondary WHO grade III meningioma. Brain Pathol. 2021;31:61-9. https://doi.org/10.1111/bpa.12892; Williams EA, Santagata S, Wakimoto H, Shankar GM, Barker FG, Sharaf R, et al. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020;8:171. https://doi.org/10.1186/s40478-020-01040-2; Barresi V, Simbolo M, Fioravanzo A, Piredda ML, Caffo M, Ghimenton C, et al. Molecular profiling of 22 primary atypical meningiomas shows the prognostic significance of 18q heterozygous loss and CDKN2A/B homozygous deletion on recurrence-free survival. Cancers (Basel). 2021;13:903. https://doi.org/10.3390/cancers13040903; Rutland JW, Gill CM, Loewenstern J, Arib H, Pain M, Umphlett M, et al. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Cancer Immunol Immunother. 2021;70:169-76. https://doi.org/10.1007/s00262-020-02671-z; Gill CM, Loewenstern J, Rutland JW, Arib H, Pain M, Umphlett M, et al. SWI/SNF chromatin remodeling complex alterations in meningioma. J Cancer Res Clin Oncol. 2021;147:3431-40. https://doi.org/10.1007/s00262-020-02671-z; Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DTW, et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 2017;133:431-44. https://doi.org/10.1007/s00401-017-1678-x; Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylationbased classification and grading system for meningioma: A multicentre, retrospective analysis. Lancet Oncol. 2017;18:682-94. https://doi.org/10.1016/S1470-2045(17)3015; Nazem AA, Ruzevick J, Ferreira MJ. Advances in meningioma genomics, proteomics, and epigenetics: Insights into biomarker identification and targeted therapies. Oncotarget. 2020;11:4544-53. https://doi.org/10.18632/oncotarget.27841; Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, et al. Octreotide therapy in meningiomas: In vitro study, clinical correlation, and literature review. J Neurosurg. 2017;127:660-9. https://doi.org/10.3171/2016.8.JNS16995; Graillon T, Defilles C, Mohamed A, Lisbonis C, Germanetti AL, Chinot O, et al. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J Neurooncol. 2015;124:33-43. https://doi.org/110.1007/s11060-015-1812-3; Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, et al. Everolimus and octreotide for patients with recurrent meningioma: Results from the Phase II CEVOREM Trial. Clin Cancer Res. 2020;26:552-7. https://doi.org/10.1158/1078-0432.CCR-19-2109; Cardona AF, Ruiz-Patiño A, Zatarain-Barrón ZL, Hakim F, Jiménez E, Mejía JA, et al. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS ONE. 2019;14:e0217340. https://doi.org/10.1371/journal.pone.0217340; Hilton DA, Shivane A, Kirk L, Bassiri K, Enki DG, Hanemann CO. Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology. 2016;36:250-61. https://doi.org/10.1111/neup.12266; Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17:116-21. https://doi.org/10.1093/neuonc/nou148; Scerrati A, Mongardi L, Visani J, Lofrese G, Cavallo MA, Fiorentino A, et al. The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: A comprehensive literature review. Expert Rev Anticancer Ther. 2020;20:197-203. https://doi.org/10.1080/14737140.2020.1736567; Franke AJ, Skelton WP, Woody LE, Bregy A, Shah AH, Vakharia K, et al. Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int. 2018;9:133. https://doi.org/10.4103/sni.sni_264_17; Unterberger A, Nguyen T, Duong C, Kondajji A, Kulinich D, Yang I. Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas. J Neurooncol. 2021;152:205-16. https://doi.org/10.1007/s11060-020-03674-7; Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383-391. https://doi.org/10.1016/S1470-2045(16)30321-7; Stögbauer L, Stummer W, Senner V, Brokinkel B. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review. Neurosurg Rev. 2020;43:903-10. https://doi.org/10.1007/s10143-019-01087-3; https://revistabiomedica.org/index.php/biomedica/article/view/6100

الاتاحة: https://revistabiomedica.org/index.php/biomedica/article/view/6100

المؤلفون: Hakim, Fernando, Ramón, Juan Fernando, Gómez, Diego F., Ghotme, Kemel A., Mejía, Juan Armando, Jimenez, Enrique, González, Martina, Jaramillo-Velásquez, Daniel, Dominguez, Maria Teresa, Araque, Yesid, Cardenas, Maria Fernanda, Vallejo, Maria del Carmen, Soto, Hugo Alfredo, Espejo, Alfonso, Martinez, Carlos Fernando, Mayorga, Maria del Pilar, Hurtado, Cethinia, Cruz, Francy, Guacaneme, Francy, Ortega, Leidy Johana, Murcia, Liliana, Bermudez, Sonia, Useche, Juan Nicolas, Niño, Maria Claudia, Cohen, Darwin, Mora, Martha Cecilia, Castelblanco, Diana Maria, Soler, Sandra Janneth, Mejía, Etelvina, Daza, Marcela

المصدر: Interdisciplinary Neurosurgery ; volume 28, page 101506 ; ISSN 2214-7519

الاتاحة: http://dx.doi.org/10.1016/j.inat.2022.101506
https://api.elsevier.com/content/article/PII:S2214751922000202?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S2214751922000202?httpAccept=text/plain

المؤلفون: Mejía, Juan Armando, Rairan, Luis Garcia, Niño, Claudia

المصدر: Neurosurgery ; ISSN 0148-396X 1524-4040

الاتاحة: http://dx.doi.org/10.1227/neu.0000000000002953
https://journals.lww.com/10.1227/neu.0000000000002953

المؤلفون: Niño, Maria Claudia, Cohen, Darwin, Mejía, Juan Armando, Gutiérrez, Javier Andrés, González, Mariana

المصدر: Neurosurgery ; volume 88, issue 4, page E370-E371 ; ISSN 0148-396X 1524-4040

الاتاحة: http://dx.doi.org/10.1093/neuros/nyaa574
http://academic.oup.com/neurosurgery/article-pdf/88/4/E370/36593074/nyaa574.pdf
https://journals.lww.com/10.1093/neuros/nyaa574

المؤلفون: Cardona, Andrés F., Ruiz-Patiño, Alejandro, Zatarain-Barrón, Zyanya Lucia, Hakim, Fernando, Jiménez, Enrique, Mejía, Juan Armando, Ramón, Juan Fernando, Useche, Nicolás, Bermúdez, Sonia, Pineda, Diego, Cifuentes, Hernando, Rojas, Leonardo, Ricaurte, Luisa, Pino, Luis Eduardo, Balaña, Carmen, Arrieta, Oscar

المساهمون: Lee, Jung Weon, Foundation for Clinical and Applied Cancer Research

المصدر: PLOS ONE ; volume 14, issue 6, page e0217340 ; ISSN 1932-6203

الاتاحة: http://dx.doi.org/10.1371/journal.pone.0217340
http://dx.plos.org/10.1371/journal.pone.0217340

المؤلفون: Mejía, Juan Armando, Garcia Rairan, Luis, Figueredo, Luisa, Niño, Claudia

المصدر: Neurosurgery ; volume 92, issue 3, page e63-e64 ; ISSN 0148-396X 1524-4040

الاتاحة: http://dx.doi.org/10.1227/neu.0000000000002303
https://journals.lww.com/10.1227/neu.0000000000002303

Additional Titles: Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado

المؤلفون: Cañas , Alejandro, Jiménez , Enrique, Hakim , Fernando, Mejía , Juan Armando, Ramón , Juan Fernando, Gómez , Diego, Jaramillo-Velásquez , Daniel, Bermúdez , Sonia, Useche , Nicolás, Pineda , Diego, Cifuentes , Hernando, Becerra, Antonio, Muñoz , Álvaro, Santoyo , Nicolás, Ruíz-Patiño , Alejandro, Sotelo , Carolina, Archila , Pilar, Rodríguez , July, Ávila , Jenny, Ordoñez-Reyes, Camila, García-Robledo , Juan Esteban, Ricaurte , Luisa, Rojas , Leonardo, Feo , Oscar, Burgos , Remberto, Ramírez , Carlos, Arrieta , Oscar, Zatarain-Barrón , Lucía, Vargas , Carlos, Carranza , Hernán, Otero , Jorge, Cardona , Andrés F.

المصدر: Biomedica; Vol. 42 No. 4 (2022); 574-590; Biomédica; Vol. 42 Núm. 4 (2022); 574-590; 2590-7379; 0120-4157

مصطلحات الفهرس: Meningioma, gain-of-function mutation, telomerase, meningoma, mutación con ganancia de función, telomerasa, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion

URL: https://revistabiomedica.org/index.php/biomedica/article/view/6100
https://revistabiomedica.org/index.php/biomedica/article/view/6100/5188
https://revistabiomedica.org/index.php/biomedica/article/view/6100/5101
https://revistabiomedica.org/index.php/biomedica/article/view/6100/5199
https://revistabiomedica.org/index.php/biomedica/article/view/6100/5188
https://revistabiomedica.org/index.php/biomedica/article/view/6100/5101
https://revistabiomedica.org/index.php/biomedica/article/view/6100/5199
*ref*/Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. “Malignancy” in meningiomas: A clinicopathologic study of 116 patients, with grading implications. Cancer. 1999;85:2046-56. https://doi.org/10.1002/(sici)1097-0142(19990501)85:9<2046:aid-cncr23>3.0.co;2-m
*ref*/Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. https://doi.org/10.1007/s00401-007-0243-4
*ref*/Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19(Suppl.5):v1-88. https://doi.org/10.1093/neuonc/nox158
*ref*/Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, et al. Mitotic index is an independent predictor of recurrence-free survival in meningioma. Brain Pathol. 2015;25:266-75. https://doi.org/10.1111/bpa.12174
*ref*/Wang YC, Chuang CC, Wei KC, Chang CN, Lee ST, Wu CT, et al. Long term surgical outcome and prognostic factors of atypical and malignant meningiomas. Sci Rep. 2016;6:35743. https://doi.org/10.1038/srep35743
*ref*/Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, et al. WHO grade II and III meningiomas: A study of prognostic factors. J Neurooncol. 2009;95:367-75. https://doi.org/10.1007/s11060-009-9934-0
*ref*/Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, et al. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun. 2017;8:186. https://doi.org/10.1038/s41467-017-00174-7
*ref*/Christiaans I, Kenter SB, Brink HC, van Os TA, Baas F, van den Munckhof P, et al. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet. 2011;48:93-7. https://doi.org/10.1136/jmg.2010.082420
*ref*/Bi WL, Abedalthagafi M, Horowitz P, Agarwalla PK, Mei Y, Aizer AA, et al. Genomic landscape of intracranial meningiomas. J Neurosurg. 2016;125:525-35. https://doi.org/10.3171/2015.6.JNS15591
*ref*/Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077-80. https://doi.org/10.1126/science.1233009
*ref*/Yuzawa S, Nishihara H, Tanaka S. Genetic landscape of meningioma. Brain Tumor Pathol. 2016;33:237-47. https://doi.org 10.1007/s10014-016-0271-7
*ref*/Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, et al. Erratum: Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017;2:26. https://doi.org/10.1038/s41525-017-0023-6
*ref*/Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol. 2002;12:183-90. https://doi.org/10.1111/j.1750-3639.2002.tb00433.x
*ref*/Youngblood MW, Miyagishima DF, Jin L, Gupte T, Li C, Duran D, et al. Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol. 2021;23:783-94. https://doi.org/10.1093/neuonc/noaa226
*ref*/Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017;19:535-45. https://doi.org/10.1093/neuonc/now235
*ref*/Smith MJ, O’Sullivan J, Bhaskar SS, Hadfield KD, Poke G, Caird J, et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet. 2013;45:295-8. https://doi.org/10.1038/ng.2552
*ref*/Tauziede-Espariat A, Parfait B, Besnard A, Lacombe J, Pallud J, Tazi S, et al. Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: A comprehensive immunophenotypical and molecular analysis. Brain Pathol. 2018;28:466-74. https://doi.org/10.1111/bpa.12524
*ref*/Vasudevan H, Braunstein S, Phillips JJ, Pekmezci M, Wu A, Reis G, et al. GENE-04. Comprehensive genomic characterization of aggressive meningiomas identifies molecular signatures that predict clinical outcomes. Neuro-Oncology. 2017;19(Suppl.6):vi92-3. https://doi.org/10.1093/neuonc/nox168.379
*ref*/Barthel FP, Wei W, Tang M, Martínez-Ledesma E, Hu X, Amin SB, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017;49:349-57. https://doi.org/10.1038/ng.3781
*ref*/Yuan P, Cao J lin, Abuduwufuer A, Wang LM, Yuan XS, Lv W, et al. Clinical characteristics and prognostic significance of TERT promoter mutations in cancer: A cohort study and a meta-analysis. PLoS ONE. 2016;11:e0146803. https://doi.org/10.1371/journal.pone.0146803
*ref*/Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, et al. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017;8:109228-37. https://doi.org/10.18632/oncotarget.22650
*ref*/Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T, et al. De novo and secondary anaplastic meningiomas: A study of clinical and histomolecular prognostic factors. Neuro Oncol. 2018;20:1113-21. https://doi.org/10.1093/neuonc/nox231
*ref*/Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108:djv377. https://doi.org/10.1093/jnci/djv377
*ref*/Spiegl-Kreinecker S, Lötsch D, Neumayer K, Kastler L, Gojo J, Pirker C, et al. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma. Neuro Oncol. 2018;20:1584-93. https://doi.org/10.1093/neuonc/noy104
*ref*/Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016;131:803-20. https://doi.org/10.1007/s00401-016-1545-1
*ref*/Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: Report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019;21:26-36. https://doi.org/10.1093/neuonc/noy137
*ref*/Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110:6021-6. https://doi.org/10.1073/pnas.1303607110
*ref*/Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018;18:241-9. https://doi.org/10.1080/14737175.2018.1429920
*ref*/Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24:184-9. https://doi.org/10.1111/bpa.12110
*ref*/Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: An individual patient data meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91:378-87. https://doi.org/10.1136/jnnp-2019-322257
*ref*/Harmancı AS, Youngblood MW, Clark VE, Coşkun S, Henegariu O, Duran D, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2018;9:16215. https://doi.org/10.1038/ncomms14433
*ref*/Maier A, Brøchner CB, Bartek J, Eriksson F, Ugleholdt H, Broholm H, et al. Mitotic and proliferative indices in WHO grade III meningioma. Cancers (Basel). 2020;12:E3351. https://doi.org/10.3390/cancers12113351
*ref*/Maier AD, Stenman A, Svahn F, Mirian C, Bartek J, Juhler M, et al. TERT promoter mutations in primary and secondary WHO grade III meningioma. Brain Pathol. 2021;31:61-9. https://doi.org/10.1111/bpa.12892
*ref*/Williams EA, Santagata S, Wakimoto H, Shankar GM, Barker FG, Sharaf R, et al. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020;8:171. https://doi.org/10.1186/s40478-020-01040-2
*ref*/Barresi V, Simbolo M, Fioravanzo A, Piredda ML, Caffo M, Ghimenton C, et al. Molecular profiling of 22 primary atypical meningiomas shows the prognostic significance of 18q heterozygous loss and CDKN2A/B homozygous deletion on recurrence-free survival. Cancers (Basel). 2021;13:903. https://doi.org/10.3390/cancers13040903
*ref*/Rutland JW, Gill CM, Loewenstern J, Arib H, Pain M, Umphlett M, et al. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Cancer Immunol Immunother. 2021;70:169-76. https://doi.org/10.1007/s00262-020-02671-z
*ref*/Gill CM, Loewenstern J, Rutland JW, Arib H, Pain M, Umphlett M, et al. SWI/SNF chromatin remodeling complex alterations in meningioma. J Cancer Res Clin Oncol. 2021;147:3431-40. https://doi.org/10.1007/s00262-020-02671-z
*ref*/Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DTW, et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol. 2017;133:431-44. https://doi.org/10.1007/s00401-017-1678-x
*ref*/Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylationbased classification and grading system for meningioma: A multicentre, retrospective analysis. Lancet Oncol. 2017;18:682-94. https://doi.org/10.1016/S1470-2045(17)3015
*ref*/Nazem AA, Ruzevick J, Ferreira MJ. Advances in meningioma genomics, proteomics, and epigenetics: Insights into biomarker identification and targeted therapies. Oncotarget. 2020;11:4544-53. https://doi.org/10.18632/oncotarget.27841
*ref*/Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, et al. Octreotide therapy in meningiomas: In vitro study, clinical correlation, and literature review. J Neurosurg. 2017;127:660-9. https://doi.org/10.3171/2016.8.JNS16995
*ref*/Graillon T, Defilles C, Mohamed A, Lisbonis C, Germanetti AL, Chinot O, et al. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas. J Neurooncol. 2015;124:33-43. https://doi.org/110.1007/s11060-015-1812-3
*ref*/Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, et al. Everolimus and octreotide for patients with recurrent meningioma: Results from the Phase II CEVOREM Trial. Clin Cancer Res. 2020;26:552-7. https://doi.org/10.1158/1078-0432.CCR-19-2109
*ref*/Cardona AF, Ruiz-Patiño A, Zatarain-Barrón ZL, Hakim F, Jiménez E, Mejía JA, et al. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS ONE. 2019;14:e0217340. https://doi.org/10.1371/journal.pone.0217340
*ref*/Hilton DA, Shivane A, Kirk L, Bassiri K, Enki DG, Hanemann CO. Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology. 2016;36:250-61. https://doi.org/10.1111/neup.12266
*ref*/Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17:116-21. https://doi.org/10.1093/neuonc/nou148
*ref*/Scerrati A, Mongardi L, Visani J, Lofrese G, Cavallo MA, Fiorentino A, et al. The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: A comprehensive literature review. Expert Rev Anticancer Ther. 2020;20:197-203. https://doi.org/10.1080/14737140.2020.1736567
*ref*/Franke AJ, Skelton WP, Woody LE, Bregy A, Shah AH, Vakharia K, et al. Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int. 2018;9:133. https://doi.org/10.4103/sni.sni_264_17
*ref*/Unterberger A, Nguyen T, Duong C, Kondajji A, Kulinich D, Yang I. Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas. J Neurooncol. 2021;152:205-16. https://doi.org/10.1007/s11060-020-03674-7
*ref*/Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383-391. https://doi.org/10.1016/S1470-2045(16)30321-7
*ref*/Stögbauer L, Stummer W, Senner V, Brokinkel B. Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review. Neurosurg Rev. 2020;43:903-10. https://doi.org/10.1007/s10143-019-01087-3

المؤلفون: Cardona-Mendoza, Andrés Felipe, Rojas Puentes, Leonardo, Wills, Beatriz, Behaine, José, Jiménez, Enrique, Hakim, Fernando, Useche, Nicolás, Bermúdez, Sonia, Arrieta, Oscar, Mejía, Juan Armando, Ramón, Juan Fernando, Carranza Isaza, Hernán, Vargas Báez, Carlos Alberto, Otero, Jorge, González, Diego, Rodríguez, July, Ortiz, León Darío, Cifuentes, Hernando, Balaña, Carmen

المساهمون: Cardona-Mendoza, Andrés Felipe 0000-0002-6697-5471, Carranza Isaza, Hernán 0000-0002-3593-7405, Vargas Báez, Carlos Alberto 0000-0002-6076-8260, Rojas Puentes, Leonardo 0000-0002-7865-5424

مصطلحات موضوعية: Biomarcador, Gliomas de bajo grado, Perfil molecular, Pronóstico, Biomarker, Hispanics, low-grade gliomas, Molecular profile, Prognosis

وصف الملف: application/pdf

Relation: Neuro-Oncology Practice, 2054-2585, Vol. 3, No. 3, 2016, p. 164-172; https://academic.oup.com/nop/article/3/3/164/2238246; http://hdl.handle.net/20.500.12495/4494; https://doi.org/10.1093/nop/npv061; instname:Universidad El Bosque; reponame:Repositorio Institucional Universidad El Bosque; repourl:https://repositorio.unbosque.edu.co

الاتاحة: https://hdl.handle.net/20.500.12495/4494
https://doi.org/10.1093/nop/npv061

المؤلفون: Cifuentes, Hernando, Jaramillo Velásquez, Daniel, Ruiz Patiño, Alejandro, Jiménez, Enrique, Hakim, Fernando, Gómez, Diego, Ramón, Juan Fernando, Mejía, Juan Armando, Salguero, Fernando, Ordoñez, Camila, Muñoz, Álvaro, Bermúdez, Sonia, Useche, Nicolas, Pineda, Diego, Ricaurte, Luisa, Zatarain Barrón, Zyanya Lucia, Rodríguez, July, Avila, Jenny, Rojas, Leonardo, Jaller, Elvira, Sotelo, Carolina, Garcia Robledo, Juan Esteban, Santoyo, Nicolas, Rolfo, Christian, Rosell, Rafael, Arrieta, Oscar, Polo Torres, Carolina, Cardona, Andrés Felipe

المساهمون: Cardona, Andrés Felipe 0000-0003-3525-4126, Polo Torres, Carolina 0000-0002-1237-4523

مصطلحات موضوعية: Amplificación, Bevacizumab, EGFR, Glioblastoma, Mutación, Osimertinib, Inhibidor de la tirosina quinasa, Amplification, Mutation, Tyrosine kinase inhibitor

وصف الملف: application/pdf

Relation: Journal of Neuro-Oncology, 0167-594X, Vol 154, Num 3, 2021, pag 353-364; https://link.springer.com/article/10.1007/s11060-021-03834-3; http://hdl.handle.net/20.500.12495/9672; https://doi.org/10.1007/s11060-021-03834-3; instname:Universidad El Bosque; reponame:Repositorio Institucional Universidad El Bosque; repourl:https://repositorio.unbosque.edu.co

الاتاحة: https://hdl.handle.net/20.500.12495/9672
https://doi.org/10.1007/s11060-021-03834-3

المؤلفون: Niño, Maria Claudia, Mejía, Juan Armando, Cohen, Darwin, Ruiz, Cristian, Oñate, Rosangélica, Díaz, Julieth, González, Mariana

المصدر: The Laryngoscope ; volume 131, issue 8 ; ISSN 0023-852X 1531-4995

الاتاحة: http://dx.doi.org/10.1002/lary.29631
https://onlinelibrary.wiley.com/doi/pdf/10.1002/lary.29631
https://onlinelibrary.wiley.com/doi/full-xml/10.1002/lary.29631

المؤلفون: Niño, Maria Claudia, Cohen, Darwin, Mejía, Juan Armando, Oñate, Rosangélica, González, Mariana, Vallejo, Carlos Arturo, Vallejo, Maria Gemma

المصدر: Canadian Journal of Anesthesia/Journal canadien d'anesthésie ; volume 68, issue 8, page 1290-1291 ; ISSN 0832-610X 1496-8975

الاتاحة: http://dx.doi.org/10.1007/s12630-021-02000-7
https://link.springer.com/content/pdf/10.1007/s12630-021-02000-7.pdf
https://link.springer.com/article/10.1007/s12630-021-02000-7/fulltext.html

المؤلفون: Niño, María Claudia, Mejía, Juan Armando, Cohen, Darwin, Mojica, Viviana, Rojas, María Fernanda, Mercado, José Darío, González, Mariana, Madrid, Guillermo

المصدر: Anesthesia & Analgesia ; volume 133, issue 2, page e20-e22 ; ISSN 0003-2999

الاتاحة: http://dx.doi.org/10.1213/ane.0000000000005610
https://journals.lww.com/10.1213/ANE.0000000000005610

المؤلفون: Niño, Maria Claudia, Cohen, Darwin, Mejía, Juan Armando, Moyano, Laura, González, Mariana, Vallejo, Maria Gemma

المصدر: Clinical Neuropharmacology ; volume 44, issue 5, page 198-199 ; ISSN 1537-162X 0362-5664

الاتاحة: http://dx.doi.org/10.1097/wnf.0000000000000468
https://journals.lww.com/10.1097/WNF.0000000000000468

المؤلفون: Niño, Maria Claudia, Cohen, Darwin, Mejía, Juan Armando, Moyano, Laura, González, Mariana, Vallejo, Maria Gemma

المصدر: Surgery ; ISSN 0039-6060

الاتاحة: http://dx.doi.org/10.1016/j.surg.2021.02.031
https://api.elsevier.com/content/article/PII:S0039606021001513?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0039606021001513?httpAccept=text/plain

المؤلفون: Cardona, Andrés F., Jaramillo-Velásquez, Daniel, Ruiz-Patiño, Alejandro, Polo, Carolina, Jiménez, Enrique, Hakim, Fernando, Gómez, Diego, Ramón, Juan Fernando, Cifuentes, Hernando, Mejía, Juan Armando, Salguero, Fernando, Ordoñez, Camila, Muñoz, Álvaro, Bermúdez, Sonia, Useche, Nicolas, Pineda, Diego, Ricaurte, Luisa, Zatarain-Barrón, Zyanya Lucia, Rodríguez, July, Avila, Jenny

المصدر: Journal of Neuro-Oncology; Sep2021, Vol. 154 Issue 3, p353-364, 12p

المؤلفون: Cardona-Mendoza, Andrés Felipe, Rojas Puentes, Leonardo, Wills, Beatriz, Bernal, Laura, Ruiz-Patiño, Alejandro, Arrieta, Oscar, Jiménez Hakim, Enrique, Hakim, Fernando, Mejía, Juan Armando, Useche, Nicolás, Bermúdez, Sonia, Carranza Isaza, Hernán, Vargas Báez, Carlos Alberto, Otero, Jorge, Mayor, Luis Carlos, Ortíz, León Darío, Franco, Sandra, Ortíz, Carlos, Gil-Gil, Miguel, Balaña, Carmen, Zatarain-Barrón, Zyanya Lucia

المساهمون: Cardona-Mendoza, Andrés Felipe 0000-0002-6697-5471, Carranza Isaza, Hernán 0000-0002-3593-7405, Vargas Báez, Carlos Alberto 0000-0002-6076-8260, Rojas Puentes, Leonardo 0000-0002-7865-5424

مصطلحات موضوعية: Anticonvulsivantes, Evaluación de medicamentos, Pirrolidinonas, Efficacy, Safety, Antiepileptic drugs, Hispanic, Glioblastoma

وصف الملف: application/pdf

Relation: Journal of Neuro-Oncology, 1573-7373, Vol 136, Num 2, 2018, pag 363-371; https://link.springer.com/article/10.1007/s11060-017-2660-0; http://hdl.handle.net/20.500.12495/2900; https://doi.org/10.1007/s11060-017-2660-0

الاتاحة: https://hdl.handle.net/20.500.12495/2900
https://doi.org/10.1007/s11060-017-2660-0